SCHEMBL6784404

SCHEMBL6784404

C/C(=C/C(=O)Cl)c1ccc(C)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.45
KMT2A Q03164 2/20 0.44
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRB2 P47870 1/20 0.40
HSD11B1 P28845 1/20 0.40
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
CYP2A6 P11509 1/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14531272 0.87 NFE2L2 (0.46) NFE2L2KMT2AFLT1FLT4KDR
Hydrochloric Acid SCHEMBL6784407 0.84 NFE2L2 (0.47) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL108320 0.78 NFE2L2 (0.47) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL27875939 0.78 TP53 (0.44) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL6785079 0.77 CYP2A6 (0.54) KMT2ASMN1; SMN2HTTLMNACYP2A6
SCHEMBL96218 0.76 KMT2A (0.51) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL29381894 0.76 KMT2A (0.51) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL7549382 0.76 NFE2L2 (0.42) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL7549381 0.76 NFE2L2 (0.42) NFE2L2KMT2AFLT1FLT4KDR
SCHEMBL6786926 0.74 SMN1; SMN2 (0.46) KMT2ASMN1; SMN2HTTLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 NFE2L2 1061/4885KMT2A 490/4885FLT1 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.